RUNX1 and acute myeloid leukemia: RUNX1 has been demonstrated to be downregulated in glioma, acute myeloblastic leukemia (AML) and gastric cancer; however, overexpression of RUNX1 in glioma, AML and gastric cancer reduced malignant progression [24].